{"brief_title": "Rotavirus Efficacy and Safety Trial (REST)(V260-006)", "brief_summary": "This study was designed to evaluate the safety of the investigational rotavirus vaccine and the efficacy to prevent rotavirus gastroenteritis.", "condition": "Rotavirus Infections", "intervention_type": "Biological", "intervention_name": "Comparator: Placebo", "description": "3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.", "arm_group_label": "2", "other_name": "V260", "criteria": "Inclusion Criteria: - Healthy infants Exclusion Criteria: - None Specified", "gender": "All", "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00090233.xml"}